Article Text

Download PDFPDF
Sex-specific troponin measures for diagnosis of acute coronary syndrome
  1. Evangelos Giannitsis
  1. Department of Internal Medicine III, Cardiology, University Hospital Heidelberg, Heidelberg, Germany
  1. Correspondence to Dr Evangelos Giannitsis, Medizinische Klinik III, Im Neuenheimer Feld 410, Heidelberg 69120, Germany; evangelos_giannitsis{at}, evangelos.giannitsis{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The present article from Cullen et al1 investigates the important question whether sex-specific cut-offs should be applied for prognostic purposes using high sensitivity cardiac troponin (cTn) assays. The article specifically addresses the effect of sex-specific cut-offs using the Architect high sensitivity troponin I assay (Abbott Diagnostics). The study enrolled 2841 patients from Australia, New Zealand and UK measuring hsTnI from frozen blood samples collected at presentation. The study applied the overall 99th centile value of a healthy reference population (26 ng/L) and sex-specific cut-offs for women (16 ng/L) and men (34 ng/L) as recommended by the manufacturer.2 A key finding of this study was that a sex-specific cut-off improved identification of women but not men at risk for myocardial infarction (MI), emergency coronary revascularisation or death within 1 year.1 In contrast, the effect of sex-specific cut-offs for more accurate diagnostic classification of suspected acute coronary syndrome (ACS) was not in the scope of this study and was found to minimally change the proportion of patients with hsTnI elevations from 9.29% with the overall cut-off to 9.15% by the use of sex-specific cut-offs. There was no significant overall net gain (NRI=−1.5%) in classification nor a net reclassification improvement for outcomes for the entire cohort for those with (NRI=−1.5%) or without major adverse cardiac events (MACE) at 1 year (NRI=−0.04%). Therefore, …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles